The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / EULAR 2014: Biosimilar Drug Production Raises Concerns

EULAR 2014: Biosimilar Drug Production Raises Concerns

August 1, 2014 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
  • EULAR 2014: Collaboration Among Rheumatology Groups Expected to Build
  • Rheumatology Drug Updates
Explore This Issue
August 2014
Also By This Author
  • The Psychosocial Toll of COVID-19

PARIS, FRANCE—Questions about biosimilars bring tremendous uncertainty to the world of rheumatology therapies, and a group of experts tried to shed light on the topic at the Annual European Congress of Rheumatology (EULAR 2014) in June, providing insights into the production of biosimilars, their regulation and potential economic effects.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Joao Goncalves, PhD, associate professor of pharmacy at the University of Lisbon, Portugal, who has helped write a position paper on the use of biosimilars for the Portuguese Society of Rheumatology, said the production of biosimilars is fraught with challenges. That the companies attempting to create them have a model to follow is only so helpful, he said.

“The biosimilar companies do not know anything about how to produce the original molecule,” Dr. Goncalves said. “They only know the sequence of the drug. They have to develop a completely innovative production method.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

These companies have to solve the problems of that production method, analyze the characteristics of the drug, analyze its mechanism of action and confirm the clinical biosimilarity.

The assessment of biosimilars has to take into account new scientific understanding of how monoclonal antibodies work—insights that weren’t known 15 years ago when the original anti-tumor necrosis factor hit the market. Most importantly, he said, is the role of glycosylation.

That is not nearly as simple as creation of a generic to an existing drug.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“When you have a generic, everything is equal,” Dr. Goncalves said. “For a biologic, it’s different—we have many possible isoforms. And the process really makes the product.”

Dr. Goncalves
Dr. Goncalves

Focus on Similarity

Inevitably, there is “passive drift,” the subtle changes over time—but acceptable to regulatory agencies—that occur with such complex compounds. But in the production process, the drug companies also insert their own “active drift”: the changing of tubing, relocating equipment or adding a new cell line.

The main idea, Dr. Goncalves said, is that the focus is on similarity and not de novo efficacy—if the similarity is present, then clinical results should follow.

The clinical upshot of biosimilars is that once the potential problems with biosimilars are identified, the risks associated with those problems can be described, and then those risks can be properly managed, Dr. Goncalves said.

Approved Biosimilars

Juan Esplugues, MD, PhD, professor of pharmacology at the University of Valencia, Spain, and an expert on biosimilars, pointed to the handling of the first two biosimilars of infliximab to illustrate the uncertainties involved in this new landscape.

Pages: 1 2 3 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Rheumatoid Arthritis, Safety Tagged With: Biosimilars, Collins, drug, EULAR, infliximab, International, Rheumatoid arthritis, rheumatologist, rheumatology, SafetyIssue: August 2014

You Might Also Like:
  • EULAR 2014: Research on Rheumatoid Arthritis, Spondyloarthritis
  • EULAR 2014: Collaboration Among Rheumatology Groups Expected to Build
  • Rheumatology Drug Updates
  • FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.